Evidence map›Paper›PMID 29671030›Full record

ArticleDiabetologia2018

Abnormal islet sphingolipid metabolism in type 1 diabetes.

Laurits J Holm, Lars Krogvold, Jane P Hasselby, Simranjeet Kaur, Laura A Claessens, Mark A Russell, Clayton E Mathews, Kristian F Hanssen, Noel G Morgan, Bobby P C Koeleman and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Lipidomic predictors of residual insulin production in adults with newly diagnosed type 1 diabetes.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  7. CD168 Identifies Proliferating Pancreatic Islet Cells in Murine and Human.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  8. Frontiers in genetics · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Beta-cell activity and development of Type 1 diabetes.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
    Review
  13. L-serine metabolic regulation and host respiratory homeostasis.Frontiers in cellular and infection microbiology · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 5 countries.

Laurits J HolmThe Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen Biocenter, Ole Maaløes Vej 5, 2200, Copenhagen N, Denmark.
Lars KrogvoldDivision of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Jane P HasselbyDepartment of Pathology, Rigshospitalet, Copenhagen, Denmark.
Simranjeet KaurSteno Diabetes Center Copenhagen, Gentofte, Denmark.
Laura A ClaessensDepartment of Immunohaematology & Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
Mark A RussellInstitute of Biomedical and Clinical Sciences, University of Exeter Medical School, Exeter, UK.
Clayton E MathewsDepartment of Pathology, University of Florida, Gainesville, FL, USA.
Kristian F HanssenFaculty of Odontology, University of Oslo, Oslo, Norway.
Noel G MorganInstitute of Biomedical and Clinical Sciences, University of Exeter Medical School, Exeter, UK.
Bobby P C KoelemanDepartment of Medical Genetics, University Medical Center, Utrecht, the Netherlands.
Bart O RoepDepartment of Immunohaematology & Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
Ivan C GerlingDepartment of Medicine, University of Tennessee, Memphis, TN, USA.
Flemming PociotSteno Diabetes Center Copenhagen, Gentofte, Denmark.
Knut Dahl-JørgensenDivision of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Karsten BuschardThe Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen Biocenter, Ole Maaløes Vej 5, 2200, Copenhagen N, Denmark. buschard@dadlnet.dk.
Rigshospitalet · DKLeiden University Medical Center · NLOslo University Hospital · NOSteno Diabetes Center · DKUniversity of Exeter · GBUniversity Medical Center Utrecht · NLUniversity of Florida · USUniversity of Oslo · NOUniversity of Tennessee Health Science Center · US

Funding

Defining Islet Heterogeneity Using Single Islet TranscriptomicsUC4DK104155 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CAMPBELL-THOMPSON, MARTHA, GERLING, IVAN C · 2014 to 2014
$1.6M
NIDDK NIH HHS UC4 DK104155NIH HHS UC4 DK104155
6 · The paper itself

Abstract

aims/hypothesisSphingolipids play important roles in beta cell physiology, by regulating proinsulin folding and insulin secretion and in controlling apoptosis, as studied in animal models and cell cultures. Here we investigate whether sphingolipid metabolism may contribute to the pathogenesis of human type 1 diabetes and whether increasing the levels of the sphingolipid sulfatide would prevent models of diabetes in NOD mice.

methodsWe examined the amount and distribution of sulfatide in human pancreatic islets by immunohistochemistry, immunofluorescence and electron microscopy. Transcriptional analysis was used to evaluate expression of sphingolipid-related genes in isolated human islets. Genome-wide association studies (GWAS) and a T cell proliferation assay were used to identify type 1 diabetes related polymorphisms and test how these affect cellular islet autoimmunity. Finally, we treated NOD mice with fenofibrate, a known activator of sulfatide biosynthesis, to evaluate the effect on experimental autoimmune diabetes development.

resultsWe found reduced amounts of sulfatide, 23% of the levels in control participants, in pancreatic islets of individuals with newly diagnosed type 1 diabetes, which were associated with reduced expression of enzymes involved in sphingolipid metabolism. Next, we discovered eight gene polymorphisms (ORMDL3, SPHK2, B4GALNT1, SLC1A5, GALC, PPARD, PPARG and B4GALT1) involved in sphingolipid metabolism that contribute to the genetic predisposition to type 1 diabetes. These gene polymorphisms correlated with the degree of cellular islet autoimmunity in a cohort of individuals with type 1 diabetes. Finally, using fenofibrate, which activates sulfatide biosynthesis, we completely prevented diabetes in NOD mice and even reversed the disease in half of otherwise diabetic animals. CONCLUSIONS/

interpretationThese results indicate that islet sphingolipid metabolism is abnormal in type 1 diabetes and suggest that modulation may represent a novel therapeutic approach. DATA AVAILABILITY: The RNA expression data is available online at https://www.dropbox.com/s/93mk5tzl5fdyo6b/Abnormal%20islet%20sphingolipid%20metabolism%20in%20type%201%20diabetes%2C%20RNA%20expression.xlsx?dl=0 . A list of SNPs identified is available at https://www.dropbox.com/s/yfojma9xanpp2ju/Abnormal%20islet%20sphingolipid%20metabolism%20in%20type%201%20diabetes%20SNP.xlsx?dl=0 .

Indexed as

AdultAnimalsAutoimmunityCase-Control StudiesCell ProliferationCells, CulturedDiabetes Mellitus, Type 1Disease Models, AnimalFemaleFenofibrateGene Expression Regulation, EnzymologicHumansIslets of LangerhansLipid MetabolismLymphocyte ActivationMaleFenofibrateSulfoglycosphingolipidsFenofibrateGene polymorphismsGWASIslet autoimmunityNOD micePreventionSphingolipidSulfatideT cellsType 1 diabetes

Identifiers

PMID29671030
PMCPMC6445476
OpenAlexW2801568488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.